Physician profile
Cale M Sebald
NPI 1609281401
$6,155.98
in general payments reported to CMS, 2019-2025
25 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $450 · 2021: $68.46 · 2022: $778 · 2023: $878 · 2024: $1,453 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $87.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.01 |
| Education | $87.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,184.41 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $668.72 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $617.82 | 2019-2025 | |
| Janssen Biotech, INC. | $600.01 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $557.68 | 2020-2025 | Xifaxan |
| Genzyme Corporation | $298.17 | 2022-2025 | |
| Pfizer INC. | $247.77 | 2020-2025 | |
| Madrigal Pharmaceuticals | $247.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $154.25 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $95.36 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $81.76 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $61.13 | 2022-2023 | |
| Celgene Corporation | $48.07 | 2023-2024 | Zeposia |
| Olympus America INC. | $40.86 | 2022-2023 | Evis Exera Lll Colonovideoscope |
| Ipsen Biopharmaceuticals, INC | $37.76 | 2024-2025 | Iqirvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.27 | 2022-2023 | Dificid |
| Amgen INC. | $32.16 | 2022 | |
| Alnylam Pharmaceuticals INC. | $31.98 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.36 | 2024 | Cyltezo |
| Capsovision, INC. | $17.16 | 2025 | Capsocam Plus |
| Shire North American Group INC | $16.99 | 2019 | |
| Ardelyx, INC. | $16.49 | 2025 | Ibsrela |
| Medtronic, INC. | $13.63 | 2025 | Gi Genius |
| Braintree Laboratories, INC. | $13.09 | 2023 | Suflave |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cale Sebald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.